Home > Boards > US OTC > Biotechs >

Xenomics Inc. (XNOM)

XNOM RSS Feed
Add XNOM Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 5/21/2010 2:58:19 AM - Followers: 1 - Board type: Free - Posts Today: 0

XNOM is a completely undiscovered stock with a very limited trading history, so it will take some time to develop the story. As time goes by, the audience for this stock will grow. The company owns the rights to develop applications for the use of transrenal DNA. To me, the is absolutely fascinating technology, and it will be very interesting to see this company develop commercial applications for this discovery. In the 1980's the medical community believed that DNA in the blood stream was filtered out through the kidneys. Russian scientists who were researching radiation poisoning from the Chenobyl disaster discovered this was not the case. DNA can provide you will a lot of information about what's happening in the body. For example, fetal DNA can be found in the mother's urine. DNA from a transplanted organ can be found in the recipients urine. DNA from cancer cells, which almost have a life of their own, can be found in urine. Heretofore, it was difficult to locate and retrieve this DNA without highly invasive surgery. In order to manage and protect the myriad of potential applications for transrenal DNA, XNOM has recruited one of the biggest guns in the industry. Dr. David Ladner has been awarded the position of Director of Licensing and Intellectual Property. There is a lot of information about Dr. Ladner in the press release below. Prior to coming over to fledgling XNOM, Dr. Lander was a manager of Intellectual Property at Bayer Pharmaceutical Division for the last five years, where he handled patent filing and prosecution for Chemical Research. He also served as Patent Liaison as well as Research Manager at American Cyanamid Co., for over 20 years, overseeing key aspects of patents and intellectual property. Dr. Ladner holds 22 patents himself, and has published widely in professional journals. As stated above, watch this one develop. I believe XNOM has remarkable potential, and clearly one industry pro who has jumped ship agrees with me. http://www.xenomics.com/Overview021.pdf http://finance.yahoo.com/q?s=xnom.ob http://www.trilogy-capital.com/tcp/xenomics CEO INTERVIEWS: http://wallst.net/superstock/XNOM/xnom.html http://www.wallst.net/audioarchive.asp http://prbroadcast.com http://prbroadcast.com/stage3/articleRead.asp?a={8E8773B7-0682-4A4A-AB42-DBAECA306986}&p=1 News: 09/08/2005 Xenomics' Novel Noninvasive Tr-DNA Technology Featured as Potential ``Amnio Alternative'' in Online News Article http://biz.yahoo.com/bw/050908/85078.html?.v=1 08/26/2005 A safer option than amnios? Xenomics is developing a prenatal urine test to detect Down syndrome http://money.cnn.com/2005/08/26/news/midcaps/xenomics/index.htm 07/26/2005 Xenomics Granted European Patent for Breakthrough Tr-DNA Technology to Detect Fetal Genetic Abnormalities http://biz.yahoo.com/bw/050727/275357.html?.v=1
XNOM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
XNOM News: Xenomics’ Preliminary Investigation Leads the Company to Believe Sequenom Willfully Manipulated its Down Syndrome Data in i... 12/17/2009 07:30:00 AM
XNOM News: Xenomics, Inc., and its Subsidiary TrovaGene, Inc., Announce Italian Patent for NPM1 Testing for AML Patients 12/15/2009 11:37:00 AM
XNOM News: Xenomics, Inc. and Its Subsidiary TrovaGene, Inc. Announce HPV Patent Filing Based on Transrenal DNA Technology 11/10/2009 07:30:00 AM
XNOM News: Xenomics, Inc. Files Suit against Sequenom, Inc. for Fraud 10/29/2009 07:30:00 AM
XNOM News: Xenomics Appoints Bruce A. Huebner as Chief Executive Officer and Board Member 10/06/2009 07:30:00 AM
Consent Preferences